company background image
AJANTPHARM logo

Ajanta Pharma NSEI:AJANTPHARM Stock Report

Last Price

₹2.23k

Market Cap

₹280.9b

7D

4.9%

1Y

84.5%

Updated

28 Mar, 2024

Data

Company Financials +

Ajanta Pharma Limited

NSEI:AJANTPHARM Stock Report

Market Cap: ₹280.9b

AJANTPHARM Stock Overview

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages.

AJANTPHARM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance5/6
Financial Health5/6
Dividends5/6

Ajanta Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ajanta Pharma
Historical stock prices
Current Share Price₹2,230.85
52 Week High₹2,353.95
52 Week Low₹1,190.15
Beta0.014
1 Month Change5.10%
3 Month Change7.06%
1 Year Change84.52%
3 Year Change91.39%
5 Year Change227.83%
Change since IPO14,143.51%

Recent News & Updates

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Recent updates

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07
These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Oct 24
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Aug 25
Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Jul 19
Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Apr 28
A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Mar 14
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06
I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07
Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14
Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10
Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11
Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24
Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On

Jan 30
The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On

What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?

Jan 18
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Jan 06
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?

Dec 25
What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?

You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend

Dec 13
You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend

Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?

Dec 01
Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting

Nov 19
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting

Shareholder Returns

AJANTPHARMIN PharmaceuticalsIN Market
7D4.9%2.4%1.8%
1Y84.5%65.8%48.6%

Return vs Industry: AJANTPHARM exceeded the Indian Pharmaceuticals industry which returned 63.9% over the past year.

Return vs Market: AJANTPHARM exceeded the Indian Market which returned 47.3% over the past year.

Price Volatility

Is AJANTPHARM's price volatile compared to industry and market?
AJANTPHARM volatility
AJANTPHARM Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: AJANTPHARM has not had significant price volatility in the past 3 months.

Volatility Over Time: AJANTPHARM's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19737,713Yogesh Agrawalhttps://www.ajantapharma.com

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as antimalarial, cardiology, ophthalmology, dermatology, pain management, gastroenterology, antihistamine, respiratory, diabetes areas. It also provides tablets, capsules, powder, liquid, jelly, ointments, sterile eye drops, active pharma ingredient.

Ajanta Pharma Limited Fundamentals Summary

How do Ajanta Pharma's earnings and revenue compare to its market cap?
AJANTPHARM fundamental statistics
Market cap₹280.90b
Earnings (TTM)₹7.36b
Revenue (TTM)₹40.36b

38.2x

P/E Ratio

7.0x

P/S Ratio

Is AJANTPHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AJANTPHARM income statement (TTM)
Revenue₹40.36b
Cost of Revenue₹11.03b
Gross Profit₹29.34b
Other Expenses₹21.98b
Earnings₹7.36b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)58.43
Gross Margin72.68%
Net Profit Margin18.23%
Debt/Equity Ratio0.9%

How did AJANTPHARM perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

62%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.